seekingalpha.com /3 weeks ago

Merck & Co., Inc. (MRK) Shareholder/Analyst Call Transcript

Read source
pharmexec.com /1 month ago

<![CDATA[Pharmaceutical Executive Daily: Merck Acquires SPR2015 in $2.13 Billion Licensing Deal]]>

Read source
dividend-growth-stocks.com /3 weeks ago

Merck & Co., Inc. (MRK) Dividend Stock Analysis

Linked here is a detailed quantitative analysis of Merck & Co., Inc. (MRK). Below are some highlights from the above linked analysis: Company Description:&nbs...

Read source
pharmexec.com /1 month ago

<![CDATA[Merck KGaA, Darmstadt, Germany, Acquires Silence Therapeutics for $1.3 Billion ]]>

Read source
pharmexec.com /2 weeks ago

<![CDATA[Lonza to Acquire Five U.S. CDMO Sites From Merck KGaA]]>

Read source
pharmexec.com /1 month ago

<![CDATA[Merck Licenses Preclinical KRAS G12D Inhibitor from SciBrunch]]>

Read source
investing.com /3 weeks ago

Merck to boost next decade revenue forecast on new drugs optimism

Read source
cafepharma.com /3 weeks ago

PCSK9 Pill - When Will Merck Start The Hiring Process ?

PCSK9 Pill - When Will Merck Start The Hiring Process ? Anonymous (not verified) Thu, 10/29/2026 - 16:22 field_thread_url https://cafepharma.com/boards/thr...

Read source
cafepharma.com /4 weeks ago

The Merck/Moderna Results

The Merck/Moderna Results Anonymous (not verified) Fri, 10/23/2026 - 13:17 pharmagather item url The Merck/Moderna Results pharmagather...

Read source
biopharmadive.com /1 month ago

Merck reveals study success, and possible safety worries, for eye drug hopeful

A medicine acquired in a $1.3 billion buyout came through in the first of two pivotal studies in diabetic macular edema, though language regarding the drug’s safety stirred debate...

Read source
pharmexec.com /1 week ago

<![CDATA[argenx Acquires Unnatural Products Inc. to Expand Immunology Capabilities ]]>

Read source
seekingalpha.com /1 month ago

Merck KGaA to buy Silence Therapeutics in all-cash deal

Read source
pharmexec.com /5 days ago

<![CDATA[M&A Roundup: Johnson & Johnson Acquires Ollin Biosciences, Eli Lilly Acquires Calytrix Bio, AmyriAD...

Read source
medcitynews.com /1 month ago

Merck Pays $400M for Cancer Drug Prospect From China-Based SciBrunch

Merck now has global rights to a SciBrunch Therapeutics drug candidate designed to block mutated versions of the cancer-driving protein KRAS G12D. This class of targeted cancer the...

Read source
investing.com /1 month ago

Merck KGaA to acquire Silence Therapeutics for $1.3 billion

Read source
medcitynews.com /1 month ago

Merck KGaA’s $1.1B Silence Therapeutics Buyout Brings RNA Drug for Rare Blood Cancer

The Silence Therapeutics acquisition gives Merck KGaA a drug ready for a pivotal test in the blood disorder polycythemia vera. Silence’s RNA therapy offers a different approach and...

Read source
medcitynews.com /1 week ago

Drug Approval Marks Another Win for Merck KGaA’s Rare Tumor Strategy

Merck KGaA drug Pimjetmi is now FDA approved for treating tenosynovial giant cell tumor. This drug complements other rare tumor assets the Germany-based drugmaker has acquired in a...

Read source
supplychain247.com /1 month ago

Merck Commits $2.9 Billion to Pennsylvania Vaccine and Drug Sites

Merck plans a $2.9 billion Pennsylvania expansion through 2030, including $550 million for West Point and Spring House research facilities.

Read source
pharmexec.com /2 weeks ago

<![CDATA[Novo Terminates Research Collaboration With Korro Bio ]]>

Read source
biopharmadive.com /1 month ago

Merck KGaA bets on RNAi with $1.3B Silence buyout

The acquisition gives the German company a promising blood disorder medicine that passed a Phase 2 test and could threaten a Takeda drug.

Read source
manufacturing-today.com /2 weeks ago

Lonza buys its way to a bigger US drug manufacturing network

Lonza has agreed to buy 5 US manufacturing sites from Merck KGaA, adding about 1,100 employees and capacity for cancer drug components and gene therapy vectors as drug production m...

Read source
pharmexec.com /1 month ago

<![CDATA[InnoCare Enters $3.35 Billion Research Collaboration and License Agreement with Eli Lilly]]>

Read source
biopharmadive.com /1 month ago

Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial

A Dutch court barred Merck from selling subcutaneous Keytruda in several European countries. Elsewhere, an Insmed executive ended a seven-year run and two startups secured venture...

Read source
labiotech.eu /1 month ago

Merck’s new BioReliance® Facility in Darmstadt: supporting biologics development and commercialization in Europe

Merck’s new BioReliance® Facility in Darmstadt, Germany, will support biologics testing, GMP release testing and stability studies in Europe. The post Merck’s new BioReliance® Faci...

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.